Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16303321 | 0.89 | KMT2A (0.48) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16297309 | 0.89 | KMT2A (0.48) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15994417 | 0.79 | KDM4E (0.43) | KDM4EGAA | |
| SCHEMBL16305485 | 0.74 | DRD2 (0.55) | POLB | |
| SCHEMBL10575371 | 0.72 | KDM4E (0.66) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4577310 | 0.72 | FAAH (0.68) | KMT2AMEN1ALDH1A1SMN1; SMN2FAAH | |
| SCHEMBL16293110 | 0.72 | KDM2B (0.38) | — | |
| SCHEMBL5789068 | 0.71 | MGLL (0.58) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL17364569 | 0.70 | KDM4E (0.42) | SMN1; SMN2KDM4EGAARAB9A | |
| SCHEMBL15995309 | 0.70 | KDM4E (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | claimed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | claimed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | KMT2A 41/4885MEN1 3081/4885ALDH1A1 1536/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | KMT2A 41/4885MEN1 3081/4885ALDH1A1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.